Health Canada has approved the use of Pfizer’s antiviral pill treatment for COVID-19.
The federal health agency says the prescription-only medication, dubbed Paxlovid, can be given to adults ages 18 who have mild to moderate cases of COVID-19 and are at a high risk of becoming more seriously ill.
The decision comes as COVID-19 cases and hospitalizations have been surging in Canada due to the Omicron variant, forcing provinces to re-enter lockdowns.
The authorization, posted on Health Canada’s site this morning, specifies scenarios in which the drug cannot be administered, including to prevent COVID-19 infections or to treat patients who are already hospitalized due to severe COVID-19 cases. The medication can’t be taken for longer than five days in a row, and isn’t greenlit for use on teens or children.
According to Pfizer, Paxlovid uses a combination of drugs to prevent the virus that causes COVID-19 from replicating itself once it’s infected a patient. Part of the pill uses ritonavir, a drug that’s been used in combination with other antiviral medications before.
Clinical trials show that there was an 89 percent reduction in the risk of being hospitalized or dying of COVID-19 in patients who received Paxlovid within three days of showing symptoms of the virus, compared to the study group that received a placebo.
Related Stories
Quebec Introduces 'Significant' Tax on Unvaccinated Canadians
Quebec will become the first Canadian province to charge a health tax to Canadians who aren’t vaccinated against COVID-19, the premier announced.
Americans Urged to 'Reconsider' Travel to Canada Due to High COVID Levels
The United States is currently urging its citizens to “reconsider travel” to Canada due to what its Centers for Disease Control call “high levels” of COVID-19.
Canada Warns Against Non-Essential Travel Again as Omicron Spreads
The announcement couldn’t come at a worse time. The busiest travel days of the year are always in December and many Canadians have already booked flights.
